172 related articles for article (PubMed ID: 19716419)
21. Overview of the mutation spectrum in familial exudative vitreoretinopathy and Norrie disease with identification of 21 novel variants in FZD4, LRP5, and NDP.
Nikopoulos K; Venselaar H; Collin RW; Riveiro-Alvarez R; Boonstra FN; Hooymans JM; Mukhopadhyay A; Shears D; van Bers M; de Wijs IJ; van Essen AJ; Sijmons RH; Tilanus MA; van Nouhuys CE; Ayuso C; Hoefsloot LH; Cremers FP
Hum Mutat; 2010 Jun; 31(6):656-66. PubMed ID: 20340138
[TBL] [Abstract][Full Text] [Related]
22. Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP.
Cong F; Schweizer L; Varmus H
Development; 2004 Oct; 131(20):5103-15. PubMed ID: 15459103
[TBL] [Abstract][Full Text] [Related]
23. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
[TBL] [Abstract][Full Text] [Related]
24. WNT signaling pathway and stem cell signaling network.
Katoh M; Katoh M
Clin Cancer Res; 2007 Jul; 13(14):4042-5. PubMed ID: 17634527
[TBL] [Abstract][Full Text] [Related]
25. Function and biological roles of the Dickkopf family of Wnt modulators.
Niehrs C
Oncogene; 2006 Dec; 25(57):7469-81. PubMed ID: 17143291
[TBL] [Abstract][Full Text] [Related]
26. Influence of an LRP5 cytoplasmic SNP on Wnt signaling and osteoblastic differentiation.
Guo J; Cooper LF
Bone; 2007 Jan; 40(1):57-67. PubMed ID: 16956801
[TBL] [Abstract][Full Text] [Related]
27. [Cytokines in bone diseases. Wnt signaling and osteoporosis-pseudoglioma syndrome].
Ozono K
Clin Calcium; 2010 Oct; 20(10):1520-5. PubMed ID: 20890034
[TBL] [Abstract][Full Text] [Related]
28. Lrp6-mediated canonical Wnt signaling is required for lip formation and fusion.
Song L; Li Y; Wang K; Wang YZ; Molotkov A; Gao L; Zhao T; Yamagami T; Wang Y; Gan Q; Pleasure DE; Zhou CJ
Development; 2009 Sep; 136(18):3161-71. PubMed ID: 19700620
[TBL] [Abstract][Full Text] [Related]
29. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6.
Holmen SL; Giambernardi TA; Zylstra CR; Buckner-Berghuis BD; Resau JH; Hess JF; Glatt V; Bouxsein ML; Ai M; Warman ML; Williams BO
J Bone Miner Res; 2004 Dec; 19(12):2033-40. PubMed ID: 15537447
[TBL] [Abstract][Full Text] [Related]
30. Hypomorphic expression of Dkk1 in the doubleridge mouse: dose dependence and compensatory interactions with Lrp6.
MacDonald BT; Adamska M; Meisler MH
Development; 2004 Jun; 131(11):2543-52. PubMed ID: 15115753
[TBL] [Abstract][Full Text] [Related]
31. Wnt signaling: a key regulator of bone mass.
Baron R; Rawadi G; Roman-Roman S
Curr Top Dev Biol; 2006; 76():103-27. PubMed ID: 17118265
[TBL] [Abstract][Full Text] [Related]
32. LRP5 and Wnt signaling: a union made for bone.
Johnson ML; Harnish K; Nusse R; Van Hul W
J Bone Miner Res; 2004 Nov; 19(11):1749-57. PubMed ID: 15476573
[No Abstract] [Full Text] [Related]
33. NMR structure of the Wnt modulator protein Sclerostin.
Weidauer SE; Schmieder P; Beerbaum M; Schmitz W; Oschkinat H; Mueller TD
Biochem Biophys Res Commun; 2009 Feb; 380(1):160-5. PubMed ID: 19166819
[TBL] [Abstract][Full Text] [Related]
34. Context-dependent activation or inhibition of Wnt-beta-catenin signaling by Kremen.
Cselenyi CS; Lee E
Sci Signal; 2008 Feb; 1(8):pe10. PubMed ID: 18314504
[TBL] [Abstract][Full Text] [Related]
35. A cell-based Dkk1 binding assay reveals roles for extracellular domains of LRP5 in Dkk1 interaction and highlights differences between wild-type and the high bone mass mutant LRP5(G171V).
Murrills RJ; Matteo JJ; Bhat BM; Coleburn VE; Allen KM; Chen W; Damagnez V; Bhat RA; Bex FJ; Bodine PV
J Cell Biochem; 2009 Dec; 108(5):1066-75. PubMed ID: 19746449
[TBL] [Abstract][Full Text] [Related]
36. Mesd binds to mature LDL-receptor-related protein-6 and antagonizes ligand binding.
Li Y; Chen J; Lu W; McCormick LM; Wang J; Bu G
J Cell Sci; 2005 Nov; 118(Pt 22):5305-14. PubMed ID: 16263759
[TBL] [Abstract][Full Text] [Related]
37. Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6.
Bourhis E; Wang W; Tam C; Hwang J; Zhang Y; Spittler D; Huang OW; Gong Y; Estevez A; Zilberleyb I; Rouge L; Chiu C; Wu Y; Costa M; Hannoush RN; Franke Y; Cochran AG
Structure; 2011 Oct; 19(10):1433-42. PubMed ID: 21944579
[TBL] [Abstract][Full Text] [Related]
38. The extracellular domain of Lrp5/6 inhibits noncanonical Wnt signaling in vivo.
Bryja V; Andersson ER; Schambony A; Esner M; Bryjová L; Biris KK; Hall AC; Kraft B; Cajanek L; Yamaguchi TP; Buckingham M; Arenas E
Mol Biol Cell; 2009 Feb; 20(3):924-36. PubMed ID: 19056682
[TBL] [Abstract][Full Text] [Related]
39. [Wnt/LRP5, a new regulation osteoblastic pathway involved in reaching peak bone masses].
Caverzasio J
Rev Med Suisse Romande; 2004 Feb; 124(2):81-2. PubMed ID: 15095618
[TBL] [Abstract][Full Text] [Related]
40. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone.
Williams BO; Insogna KL
J Bone Miner Res; 2009 Feb; 24(2):171-8. PubMed ID: 19072724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
